RNA Modification by m⁶A Methylation in Cardiovascular Disease

Area of Science:

• Epigenetics
• Molecular Biology
• Cardiovascular Science

Background:

• Cardiovascular disease is a leading global cause of death with poorly understood regulatory mechanisms.
• N6-Methyladenosine (m6A) RNA methylation, an epigenetic modification, influences RNA processing and has been implicated in various diseases.
• m6A RNA methylation was identified in 1974 and rediscovered in 2012 with advances in sequencing technology.

Purpose of the Study:

• To review the molecular and cellular functions of m6A methylation in the cardiovascular system.
• To summarize the roles of m6A readers, writers, and erasers in cardiovascular health and disease.
• To discuss future research directions and therapeutic potential of m6A targeting in cardiovascular disease.

Main Methods:

• Literature review of m6A RNA methylation.
• Analysis of m6A regulatory mechanisms in the cardiovascular system.
• Synthesis of current research on m6A effectors (e.g., METTL3, FTO, ALKBH5) in cardiovascular diseases.

Main Results:

• m6A methylation plays critical roles in RNA splicing, nuclear export, translation, and degradation.
• Specific m6A "writers" (e.g., METTL3), "erasers" (e.g., FTO, ALKBH5), and "readers" (e.g., YTHDFs) are involved in cardiovascular regulation.
• Dysregulation of m6A pathways is linked to the development and progression of cardiovascular diseases.

Conclusions:

• m6A RNA methylation is a key epigenetic regulator with significant implications for cardiovascular function.
• Understanding m6A mechanisms offers potential for novel therapeutic strategies targeting cardiovascular diseases.
• Further research is needed to fully elucidate the complex roles of m6A in the cardiovascular system.